Gonorrhea

Treatment and management considerations for the male patient

Brian Dalke, Timothy Ivers, Karen K. O’Brien, Shana Castillo, Eric Hoie, Kimberley J. Begley

Research output: Contribution to specialist publicationArticle

Abstract

Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

Original languageEnglish (US)
Pages41-44
Number of pages4
Volume41
No8
Specialist publicationU.S. Pharmacist
StatePublished - Aug 1 2016

Fingerprint

Gonorrhea
Cefixime
Azithromycin
Ceftriaxone
Fluoroquinolones
Cephalosporins
Neisseria gonorrhoeae
Health
Centers for Disease Control and Prevention (U.S.)
Sexually Transmitted Diseases
Communicable Diseases
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Cite this

Dalke, B., Ivers, T., O’Brien, K. K., Castillo, S., Hoie, E., & Begley, K. J. (2016). Gonorrhea: Treatment and management considerations for the male patient. U.S. Pharmacist, 41(8), 41-44.

Gonorrhea : Treatment and management considerations for the male patient. / Dalke, Brian; Ivers, Timothy; O’Brien, Karen K.; Castillo, Shana; Hoie, Eric; Begley, Kimberley J.

In: U.S. Pharmacist, Vol. 41, No. 8, 01.08.2016, p. 41-44.

Research output: Contribution to specialist publicationArticle

Dalke, B, Ivers, T, O’Brien, KK, Castillo, S, Hoie, E & Begley, KJ 2016, 'Gonorrhea: Treatment and management considerations for the male patient' U.S. Pharmacist, vol. 41, no. 8, pp. 41-44.
Dalke B, Ivers T, O’Brien KK, Castillo S, Hoie E, Begley KJ. Gonorrhea: Treatment and management considerations for the male patient. U.S. Pharmacist. 2016 Aug 1;41(8):41-44.
Dalke, Brian ; Ivers, Timothy ; O’Brien, Karen K. ; Castillo, Shana ; Hoie, Eric ; Begley, Kimberley J. / Gonorrhea : Treatment and management considerations for the male patient. In: U.S. Pharmacist. 2016 ; Vol. 41, No. 8. pp. 41-44.
@misc{67fabf5d7f3b44b08b3682c139423db3,
title = "Gonorrhea: Treatment and management considerations for the male patient",
abstract = "Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5{\%} in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.",
author = "Brian Dalke and Timothy Ivers and O’Brien, {Karen K.} and Shana Castillo and Eric Hoie and Begley, {Kimberley J.}",
year = "2016",
month = "8",
day = "1",
language = "English (US)",
volume = "41",
pages = "41--44",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Gonorrhea

T2 - Treatment and management considerations for the male patient

AU - Dalke, Brian

AU - Ivers, Timothy

AU - O’Brien, Karen K.

AU - Castillo, Shana

AU - Hoie, Eric

AU - Begley, Kimberley J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

AB - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

UR - http://www.scopus.com/inward/record.url?scp=84983070756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983070756&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 41

EP - 44

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -